<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03275740</url>
  </required_header>
  <id_info>
    <org_study_id>B7801001</org_study_id>
    <secondary_id>2018-003315-21</secondary_id>
    <nct_id>NCT03275740</nct_id>
  </id_info>
  <brief_title>A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347</brief_title>
  <official_title>A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, FIRST-IN-HUMAN TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF PF-06755347 AFTER SINGLE ASCENDING INTRAVENOUS AND SUBCUTANEOUS DOSING TO HEALTHY ADULT MALE PARTICIPANTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 1 single ascending dose study will provide a first in human assessment of safety&#xD;
      and tolerability of PF-06755347 in healthy adult male subjects. The pharmacokinetics and&#xD;
      pharmacodynamics will also be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>single ascending dose study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blind (investigator and subject), sponsor open</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)</measure>
    <time_frame>Baseline (study day -2) through study completion (study day 36 for intravenous dose cohorts 1 - 6, and study day 71 for subcutaneous dose cohorts 1 - 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinical Laboratory Abnormalities</measure>
    <time_frame>Baseline, study days 2, 4, 6, 8, 11, 15, 22, 29 and 36 for i.v. dose cohorts 1 - 6, and Baseline, study days 2, 3, 4, 6, 8, 11, 15, 22, 29, 36, 50 and day 71 for subcutaneous dose cohorts 1 - 5.</time_frame>
    <description>Safety laboratory includes Hematology, Chemistry, Urinalysis, prothrombin time/international normalized ratio, partial thromboplastin time, D dimer, and fibrinogen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Categorical Vital Signs Data</measure>
    <time_frame>Baseline, study days 1, 2, 3, 4, 6, 8, 11, 15, 22, and day 36 for i.v. dose cohorts 1 - 6 and Baseline, study days 1, 2, 3, 4, 6, 8, 11, 15, 22, 29, 36, 50 and day 71 for subcutaneous dose cohorts 1 - 3.</time_frame>
    <description>Vital signs include blood pressure, pulse rate, and oral body temperature. Number of participants with maximum increase from Baseline in sitting SBP and DBP of greater than or equal to 30 mmHg will be reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Electrocardiogram (ECG)</measure>
    <time_frame>Baseline (study day 1, pre-dose), study days 1 (post dose), 2, 4, 6, 8, 11, 22, 36 (end of study visit for intravenous dose cohorts 1 - 6, and end of study visit day 71 for subcutaneous dose cohorts 1 - 5</time_frame>
    <description>Criteria for ECG abnormalities: maximum PR interval &gt;=300 milliseconds (msec) and maximum increase PR interval increase from baseline (IFB): percent change (Pctchg) &gt;=25 percent (%) for baseline value of &gt;200 msec and Pctchg&gt;=50% for baseline value of &lt;=200 msec for PR interval, maximum QRS interval &gt;=140 msec and a maximum IFB: Pctchg&gt;=50%, maximum QTCF interval (Fridericia's Correction) of 450 msec to &lt;480 msec, 480 msec to &lt;500 msec or &gt;=500 msec and a maximum change of &lt;=30change&lt;60 or &gt;=60 msec from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Baseline, 1, 3, 4, 5, 6, 8, 12 &amp; 24 hours post dose for i.v. cohorts and baseline, 6 &amp; 12 hours for subcutaneous cohorts. Study days 3, 4, 6, and 8 for i.v. dose cohorts 1-2, plus days 15, 22, 29, 36, 50 and 71 for i.v. cohorts 3 - 6 and subcu cohorts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized Maximum Observed Plasma Concentration Cmax</measure>
    <time_frame>Baseline, 1, 3, 4, 5, 6, 8, 12 &amp; 24 hours post dose for i.v. cohorts and baseline, 6 &amp; 12 hours for subcu cohorts. Study days 3, 4, 6, and 8 for i.v. dose cohorts 1-2, plus days 15, 22, 29, 36, 50 and 71 for i.v. cohorts 3 - 6 and subcu cohorts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>Baseline, 1, 3, 4, 5, 6, 8, 12 &amp; 24 hours post dose for i.v. cohorts and baseline, 6 &amp; 12 hours for subcutaneous cohorts. Study days 3, 4, 6, and 8 for i.v. dose cohorts 1-2, plus days 15, 22, 29, 36, 50 and 71 for i.v. cohorts 3 - 6 and subcu cohorts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</measure>
    <time_frame>Baseline, 1, 3, 4, 5, 6, 8, 12 &amp; 24 hours post dose for i.v. cohorts and baseline, 6 &amp; 12 hours for subcutaneous cohorts. Study days 3, 4, 6, and 8 for i.v. dose cohorts 1-2, plus days 15, 22, 29, 36, 50 and 71 for i.v. cohorts 3 - 6 and subcu cohorts</time_frame>
    <description>Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</measure>
    <time_frame>Baseline, 1, 3, 4, 5, 6, 8, 12 &amp; 24 hours post dose for i.v. cohorts and baseline, 6 &amp; 12 hours for subcu cohorts. Study days 3, 4, 6, and 8 for i.v. dose cohorts 1-2, plus days 15, 22, 29, 36, 50 and 71 for i.v. cohorts 3 - 6 and subcu cohorts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)</measure>
    <time_frame>Baseline, 1, 3, 4, 5, 6, 8, 12 &amp; 24 hours post dose for i.v. cohorts and baseline, 6 &amp; 12 hours for subcu cohorts. Study days 3, 4, 6, and 8 for i.v. dose cohorts 1-2, plus days 15, 22, 29, 36, 50 and 71 for i.v. cohorts 3 - 6 and subcu cohorts</time_frame>
    <description>AUCinf = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)</measure>
    <time_frame>Baseline, 1, 3, 4, 5, 6, 8, 12 &amp; 24 hours post dose for i.v. cohorts and baseline, 6 &amp; 12 hours for subcu cohorts. Study days 3, 4, 6, and 8 for i.v. dose cohorts 1-2, plus days 15, 22, 29, 36, 50 and 71 for i.v. cohorts 3 - 6 and subcu cohorts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2)</measure>
    <time_frame>Baseline, 1, 3, 4, 5, 6, 8, 12 &amp; 24 hours post dose for i.v. cohorts and baseline, 6 &amp; 12 hours for subcu cohorts. Study days 3, 4, 6, and 8 for i.v. dose cohorts 1-2, plus days 15, 22, 29, 36, 50 and 71 for i.v. cohorts 3 - 6 and subcu cohorts</time_frame>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL)</measure>
    <time_frame>Baseline, 1, 3, 4, 5, 6, 8, 12 &amp; 24 hours post dose for i.v. cohorts and baseline, 6 &amp; 12 hours for subcu cohorts. Study days 3, 4, 6, and 8 for i.v. dose cohorts 1-2, plus days 15, 22, 29, 36, 50 and 71 for i.v. cohorts 3 - 6 and subcu cohorts</time_frame>
    <description>Steady state total body clearance equals infusion rate (zero order) divided by steady state plasma concentration of study drug (R0/Css)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Anti-Drug Antibody (ADA)</measure>
    <time_frame>Baseline, study days 8, 15, and 36 for all dose cohorts plus day 71 for subcu cohorts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterisation of biomarker changes</measure>
    <time_frame>Baseline (study day 1, pre-dose), 1, 3, 5, 8, and 24 hours post dose, study days 3, 4, 8, 15, and day 36 for i.v. cohorts and study day 71 for sub cu dose cohorts</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">67</enrollment>
  <condition>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating</condition>
  <condition>Primary Immune Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>PF-06755347 intravenous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravenous administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo intravenous</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intravenous administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06755347 subcutaneous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subcutaneous administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo subcutaneous</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subcutaneous administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06755347 intravenous</intervention_name>
    <description>Single doses of PF-06755347 will be administered intravenously dose levels 1, 2, 3, 4, 5, and 6.</description>
    <arm_group_label>PF-06755347 intravenous</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo intravenous</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Placebo intravenous</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06755347 subcutaneous</intervention_name>
    <description>single doses of PF-06755347 will be administered subcutaneously at dose levels of SC1, SC2, SC3, SC4, and SC5.</description>
    <arm_group_label>PF-06755347 subcutaneous</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo subcutaneous</intervention_name>
    <description>placebo comparator</description>
    <arm_group_label>Placebo subcutaneous</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male participants who, at the time of screening, are between the ages of 18&#xD;
             and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities&#xD;
             identified by a detailed medical history, full physical examination, including oral&#xD;
             temperature, blood pressure (BP) and pulse rate measurement, pulse oximetry, 12 lead&#xD;
             ECG or clinical laboratory tests.&#xD;
&#xD;
          -  Evidence of a personally signed and dated informed consent document indicating that&#xD;
             the subject has been informed of all pertinent aspects of the study.&#xD;
&#xD;
          -  Chest X ray with no evidence of current, active tuberculosis (TB) or previous inactive&#xD;
             TB, general infections, heart failure, malignancy, or other clinically significant&#xD;
             abnormalities taken at Screening or within 3 months prior to Screening and read by a&#xD;
             qualified radiologist.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or&#xD;
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,&#xD;
             seasonal allergies at the time of dosing).&#xD;
&#xD;
          -  Participants with a history of autoimmune disorders and other conditions that&#xD;
             compromise or impair the immune system (including but not limited to: Crohns Disease,&#xD;
             rheumatoid arthritis, scleroderma, systemic lupus erythematosus, Graves disease, and&#xD;
             asthma) or have a current positive result for the following; rheumatoid factor,&#xD;
             anti-nuclear antibody, or abnormal free triiodothyronine (T3), free thyroxine (T4),&#xD;
             thyroid stimulating hormone (TSH), or thyroid stimulating antibody (TSAb) suggestive&#xD;
             of thyroid disease.&#xD;
&#xD;
        Subjects with a history of allergic or anaphylactic reaction to any drug including&#xD;
        immunoglobulin.&#xD;
&#xD;
          -  History of active infections within 28 days prior to the screening visit.&#xD;
&#xD;
          -  Subjects with a history of or current positive results for any of the following&#xD;
             serological tests: Hepatitis B surface antigen (HepBsAg), Hepatitis B core antibody&#xD;
             (HepBcAb), Hepatitis C antibody (HCVAb) or human immunodeficiency virus (HIV).&#xD;
&#xD;
          -  Subjects with a history of thromboembolic events or current positive result for&#xD;
             anti-cardiolipin antibody.&#xD;
&#xD;
          -  History of TB or active, latent or inadequately treated TB infection. All positive TB&#xD;
             test result(s) are exclusionary&#xD;
&#xD;
          -  Male subjects with partners currently pregnant; male subjects able to father children&#xD;
             who are unwilling or unable to use a highly effective method of contraception as&#xD;
             outlined in this protocol for the duration of the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pfizer New Haven Clinical Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Pfizer Clinical Research Unit</name>
      <address>
        <city>Brussels</city>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NZCR (New Zealand Clinical Research) OPCO Limited</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hammersmith Medicines Research (HMR)</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>New Zealand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B7801001</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 6, 2017</study_first_submitted>
  <study_first_submitted_qc>September 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2017</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyradiculoneuropathy</mesh_term>
    <mesh_term>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

